Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment
Cancer Letters · 2024-11 · 604 · 217260
DOI: 10.1016/j.canlet.2024.217260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Paul T Winnard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, Bone Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: FAMRI.
Abstract (Originalsprache)
Patients who present with breast cancer bone metastasis only have limited palliative treatment strategies and efficacious drug treatments are needed. In breast cancer patient data, high levels of the RNA helicase DDX3 are associated with poor overall survival and bone metastasis. Consequently, our objective was to target DDX3 in a mouse breast cancer bone metastasis model using a small molecule inhibitor of DDX3, RK-33. Histologically confirmed live imaging indicated no bone metastases in the RK-33 treated cohort, as opposed to placebo-treated mice. We generated a cell line from a bone metastatic lesion in mouse and found that it along with a patient-derived bone metastasis cell line gained resistance to conventional chemotherapeutics but not to RK-33. Finally, differential levels of DDX3 were observed in breast cancer patient metastatic bone samples. Overall, this study indicates that DDX3 is a relevant clinical target in breast cancer bone metastasis and that RK-33 can be a safe and effective treatment for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
- Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA; Department of Medical Oncology, University Medical Center Utrecht Cancer Center, GA, Utrecht, the Netherlands.
- Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Locked Bag 2000, Brisbane, QLD, 4029, Australia.
- Department of Pathology, University Medical Center Utrecht Cancer Center, 3508 GA, Utrecht, the Netherlands.
- Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA; Department of Pathology, University Medical Center Utrecht Cancer Center, 3508 GA, Utrecht, the Netherlands.
Förderung
- FAMRI
Zitieren
APA
Winnard, P. T., Vesuna, F., Bol, G. M., Gabrielson, K. L., Chenevix-Trench, G., Ter Hoeve, N. D., van Diest, P. J., & Raman, V. (2024). Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment. Cancer Letters, 604, 217260. https://doi.org/10.1016/j.canlet.2024.217260
Vancouver
Winnard PT, Vesuna F, Bol GM, Gabrielson KL, Chenevix-Trench G, Ter Hoeve ND, et al. Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment. Cancer Letters. 2024;604:217260. doi:10.1016/j.canlet.2024.217260
BibTeX
@article{Winnard2024,
author = {Winnard, Paul T and Vesuna, Farhad and Bol, Guus M and Gabrielson, Kathleen L and Chenevix-Trench, Georgia and Ter Hoeve, Natalie D and van Diest, Paul J and Raman, Venu},
title = {Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment},
journal = {Cancer Letters},
year = {2024},
volume = {604},
pages = {217260},
doi = {10.1016/j.canlet.2024.217260}
}
EUVIMED